Page last updated: 2024-11-07

aloe emodin anthrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aloe emodin anthrone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122840
CHEMBL ID415019
CHEBI ID80709
SCHEMBL ID12774916
MeSH IDM0165841

Synonyms (25)

Synonym
NCI60_020624
nsc-658578
6247-99-0
aloe-emodin-9-anthrone
nsc658578
9(10h)-anthracenone, 1,8-dihydroxy-3-(hydroxymethyl)-
1,8-dihydroxy-3-(hydroxymethyl)-10h-anthracen-9-one
aloeemodinanthron
CHEMBL415019 ,
chebi:80709 ,
aloe emodin anthrone
1,8-dihydroxy-3-hydroxymethyl-10h-anthracen-9-one
bdbm50060851
unii-j1gp8v92mp
ae-anthrone
nsc 658578
j1gp8v92mp ,
SCHEMBL12774916
DTXSID20211510
1,8-dihydroxy-3-(hydroxymethyl)anthrone
1,8-dihydroxy-3-(hydroxymethyl)-9(10h)-anthracenone
anthrone, 1,8-dihydroxy-3-(hydroxymethyl)-
Q27149743
1,8-dihydroxy-3-(hydroxymethyl)-9(10 h)-anthracenone
AKOS040750340
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anthracenesCompounds containing an anthracene skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-lipoxygenase Bos taurus (cattle)IC50 (µMol)30.00000.18001.75824.0000AID160507
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1605075-LO inhibitory activity was determined by inhibition of LTB4 biosynthesis in bovine polymorphonuclear leukocytes (PMNL)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID233179Antioxidant potential was assessed from reducing activity against 2,2,di-phenyl-1-picrylhydrazyl.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID85482Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID231071Peroxidant property was expressed as ratio of uMol of malondialdehyde and mMol of deoxyribose released by 75 uM test compound1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID85486Cytotoxic activity (2 uM) was measured by the amount of LDH (mU) release in HaCaT cells.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID19630Partition coefficient (logP)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's3 (18.75)18.2507
2000's12 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.78 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]